The rare disease landscape has changed over the last several years. The pharmaceutical industry has begun to pay more attention to rare diseases, drawn by government incentives and the greater likelihood that treatments will be successful.
The launch of a rare disease treatment needs a different approach from the standard launch framework.
Hit the download button to get a PDF copy of the report
Related Insights & Outlooks
Migraine Key Catalysts for 2023
Atacana Group
•
June 1, 2023
While there is no cure for migraine, pharmaceutical companies continue to innovate to provide treatment options for patients suffering from migraine.
Novel and Emerging Treatments in Spinal Muscular Atrophy
Atacana Group
•
June 1, 2023
Marketed products are being evaluated for age expansion, dose increase, and in previously treated SMA patients
Antiviral Vaccines 2024 & 2025 Catalysts Report
Atacana Group
•
April 19, 2024
The Leading companies in the Antiviral Vaccine market, such as Pfizer, Moderna, GSK, and AstraZeneca are anticipating pivotal advancements, including regulatory milestones, clinical trial updates, and strategic product launches.
.avif)